Results
Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS GuidanceGuidance raised
4– Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
– Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
Outlook
5– Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1Guidance reaffirmed
1– Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58Guidance raised
Capital return
– Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases
Results
Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
Outlook
6Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 .Guidance reaffirmed
2Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.Guidance raised
Corporate events
In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial.
This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor.
By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device.
Management commentary
In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC.
"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott.
"We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
SECOND-QUARTER BUSINESS OVERVIEW
Results
Comparable sales growth:
Second Quarter 2026 Results (2Q26)
First Half 2026 Results (1H26)
Nutrition
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)TotalPediatricAdult
U.S.871525346
International1,273500773
Total reported2,1441,0251,119
Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025.
These pricing actions, together with the launch of new products, are contributing to improving performance.
3Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)TotalPediatricAdult
U.S.1,7151,036679
International2,4469421,504
Total reported4,1611,9782,183
Second Quarter 2026 Results (2Q26)
Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.
Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.
Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.
8Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users.
Results in the quarter also reflect contributions to growth from the precision oncology and international businesses.
First Half 2026 Results (1H26)
Corporate events
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business.
On March 23, 2026, Abbott completed the acquisition of Exact Sciences.
Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Results
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)TotalKey Emerging MarketsOther
International1,4991,164335
Total reported1,4991,164335
Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio.
Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)TotalKey Emerging MarketsOther
U.S.
International2,9252,253672
Total reported2,9252,253672
Medical Devices
Second Quarter 2026 Results (2Q26)
Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.
7Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.
In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis.
First Half 2026 Results (1H26)
Corporate events
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026.
As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
Outlook
Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 .
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.
Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46 .
Capital return
Abbott Declares 410 th Consecutive Quarterly Dividend
On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share.
Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
Results
In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor.
Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.
38 boilerplate lines (safe-harbor disclaimer, contacts, call details) are set aside.